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NADPH oxidase (nicotinamide adenine dinucleotide phosphate-oxidase), with its generically 
termed NOX isoforms, is the major source of ROS (reactive oxigen species) in biological systems. The 
oxidant/ antioxidant imbalance in favor of oxidants in the vascular system generates ROS via activation of 
NADPH oxidase. ROS are small oxygen-derived molecules with an important role in various biological 
processes (physiological or pathological). Some processes are beneficial and necessary for life under 
physiological conditions, but they are noxious, harmful under pathophysiological conditions. NADPH 
oxidases are present in phagocytes and in a wide variety of nonphagocytic cells. The enzyme generates 
superoxide by transferring electrons from NADPH inside the cell across the membrane and coupling them 
to molecular oxygen to produce superoxide anion, a reactive free-radical. Structurally, NADPH oxidase is 
a multicomponent enzyme which includes two integral membrane proteins, glycoprotein gp91phox and 
adaptor protein p22phox, which together form the heterodimeric flavocytochrome b558 that constitutes the 
core of the enzyme. During the resting state, the multidomain regulatory subunits p40phox, p47phox, p67phox 
are located in the cytosol organized as a complex. The activation of phagocytic NADPH oxidase occurs 
through a complex series of protein interactions. The increased production of free radicals under 
pathophysiological conditions is an integral part of the production of cardiovascular diseases and in 
particular of atherosclerosis. At the onset and progression of atherosclerosis, various non-traditional 
intercorrelated risk factors contribute such as oxidative stress, inflammation and endothelial dysfunction. 
Oxidative stress plays a crucial role not only in the formation but also in the evolution and destabilization 
of lesions. Oxidative stress is closely linked to endothelial damage. Endothelium modulates vascular tone by 
releasing specific vasoactive substances. At the onset and progression of atherosclerosis contributes to 
decreasing the bioavailability of NO (nitric oxide) or EDRF (endothelium-derived relaxing factor) with an 
important role in conserving vasodilation and inhibiting vasoconstriction. Clinical and paraclinical 
investigations show that inflammatory reactions operate at all stages of atherosclerotic events. According to 
the theory of oxidative stress, atherosclerosis is also the result of the particularly oxidative changes of LDL 
(low density lipoproteins) in the arterial wall. Excess ROS can produce peroxinitrite with NO, the cytotoxic 
oxidant important mediator of LDL oxidation with proaterogenic action. 
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Introduction 
Reactive oxygen species, conventionally seen as harmful end-products resulting from 
aerobic metabolism, have received special attention due to multiple cellular sources, cellular 















Among the many sources of ROS in biological systems, including the vascular system, the family 
of redox enzymes - NADPH oxidases (NOXs) [1]. Reactive oxygen species (ROS) were considered 
as phagocytic origin initially. Their function as body defense (antimicrobin, antifungal, 
antibacterial) has been shown. Subsequent research has shown that similar NADPH oxidases 
(isoforms) have also been described in a wide variety of non-phagocytic (somatic) cells that slowly 
and sustained generate intracellular O2- in different compartments (intracellular, extracellular). [1, 
2, 3] The production of ROS (O2-, H2O2) by NADPH oxidase is achieved through the catalytic 
subunit of NOX which differentiates it from other oxidases. [4] Although all NOXs isoforms have 
the same primary function in generating ROS of whatever origin, they differ from several points 
of view: structural, functional, regulatory factors, component subunit requirements, cellular and 
subcellular distribution, as well as contributing to the development various pathological conditions, 
including cardiovascular diseases. [1, 3, 5, 6, 7, 8, 9] While phagocytic NADPH oxidases become 
active after stimulation to produce superoxide radical anion, NADPH somatic oxides by the 
catalytic subunit are continuously active as a slow and sustained intracellular source of O2. ROSs 
resulting from the NADPH oxidase family members activity by the NOX subunit act as 
intracellular signaling molecules, important regulators of key biological activities such as cell 
growth, proliferation, differentiation, migration, apoptosis.[10] 
Produced in excess (condition of oxidative stress) ROS reacts indiscriminately. They may 
cause irreversible alterations in most biological molecules which also affects important cellular 
functions contributing to a wide variety of conditions such as inflammation, endothelial 
dysfunction, cardiovascular disease, hypertension, diabetes, chronic kidney disease, cardiac 
hypertrophy, stroke etc. [11, 12] There is a complex pathophysiological process in the development 
of atherosclerosis involving oxidative stress, inflammation, endothelial dysfunction, NO 
production, etc. In this context, the paper presents recent data from the literature on the oxidative 
stress triad, endothelial dysfunction, inflammation that serves as a basis for the development and 




Fig. 1: The relationship between oxidative stress, inflammation, endothelial dysfunction, 





Oxidative stress in the pathogenesis of atherogenesis 
In recent years, a huge amount of data has accumulated that support the direct link between 
excess free radicals (ROS) that causes oxidative stress (redox status) in different compartments 
(intracellular, extracellular) and most known diseases, including atherosclerosis. In this regard, it 
is proven by numerous experimental and clinical studies that oxidative stress is closely linked to 
various risk factors for atherosclerosis, such as hypercholesterolemia, hypertension, diabetes, 
smoking. 
The importance of ROS in vascular physiology and pathology under oxidative stress 
conditions is obviously increasing because several vascular sources (endothelial cells, vascular 
smooth muscle cells, fibroblasts), infiltrating immune cells contribute to the production of ROS 
mainly via NADPH oxidase non-phagocytic. [14] Both basal and stimulated NOX activity occurs 
in all segments of the vascular wall (intimate, media, adventitia), where these immune cells can 
reach. 
Into the vascular system are expressed the major isoforms of NADPH oxidase - NOX1, 
NOX2, NOX4 and NOX5 that differ by distribution, different mechanisms of activation, response 
to a wide variety of heterogeneous factors (physical, chemical, environmental or biological) and 
by potential contribution to vascular disease [15, 16], so that NOX as ROS in the vascular system 
can have both beneficial effects that in the context of physiological conditions maintain major 
vascular processes as well as harmful effects under overproduction conditions of reactive species 
derived from oxygen. [16] Oxidative stress caused by risk factors is a major cause of endothelial 
dysfunction. 
Endothelial dysfunction and oxidative stress 
The endothelium plays a critical role in regulating vascular function by releasing paracrine 
factors that maintain vascular tone, inhibits platelets and adhesion of inflammatory cells, promotes 
fibrinolysis, and limits vascular proliferation. Vasodilatation is mainly mediated by factors such as 
NO or relaxation factor derived from endothelium derived-relaxing factor (EDRF) and prostacyclin 
while vasoconstriction is mediated by factors such as endothelin-1, angiotensin II, thromboxane 
A2, prostaglandin H2. [17, 18, 19] 
Endothelial dysfunction (vascular endothelium) is characterized by modifying the 
properties of endothelial vasodilation consisting of the reduced pro-inflammatory state, 
prothrombotic status. Endothelium is a selective and metabolically active barrier that plays a 
crucial role in regulating vascular homeostasis by maintaining a delicate balance between 
vasodilatation and vasoconstriction. [17, 18] 
Endothelial dysfunction, oxidative stress, inflammation and dyslipidemia play a vital and 
vital role in the development and progression of atherosclerotic lesions. Under physiological 
conditions, endothelium controls vascular inflammation by releasing NO. Endothelial dysfunction 
can be regarded as a primum movens of atherosclerotic disease characterized mainly by endothelial 
overproduction of ROS (as O2) to lower bioavailability of the NO precursor recognized as the start 
of atherosclerosis and increase reverse angiotensin II in the vascular injury is caused by inducing 
the generation of oxidative species by activating NADPH oxidase. [12] 
Endothelial function is impaired in the early stages of atherogenesis, and is closely related 
to the atherosclerotic risk factors. [19] NO production is crucial for maintaining normal endothelial 
vascular integrity. NO as a vasodilator at physiological (nanomolar) concentrations mediates 
endothelial protective functions by inhibiting neutrophil activation and adhesion, adhesion and 
platelet aggregation, vascular smooth muscle proliferation, proinflammatory cytokine expression, 
prevention of development and complications of atherosclerosis. Numerous experimental and 





factors. Oxidative stress caused by risk factors is the major cause of endothelial dysfunction as a 
common condition predisposing to atherosclerosis. Endothelial dysfunction predisposes to 
atherosclerotic lesions and has been proposed as an important diagnostic and prognostic factor for 
coronary syndromes. Endothelium and its major NO product are key regulators of vascular 
function. The pathogenesis of endothelial dysfunction is multifactorial in which oxidative stress 
appears to be the common cellular mechanism. [18] Increased production of ROS reduces the 
production and consequently the bioavailability of NO that results in vasoconstriction, platelet 
aggregation, and adhesion of neutrophils to the endothelium. Also, the interaction of O2- with NO 
leads to peroxynitrite, a less effective substance for activating guanilyl cyclase, and thus the 
bioavailability of NO becomes particularly low. 
NADPH oxidize in the regulation of vascular inflammation 
Inflammation and oxidation are two closely related basic processes, which support the 
pathogenesis of most disease states in humans. These two distinct mechanisms (inflammation and 
oxidation) are constantly reciprocal, with obvious interactions in the vascular wall. [16, 20] Both 
processes are simultaneously encountered in many pathological conditions [21, 22] including 
cardiovascular diseases. [23] Traditionally, vascular inflammation begins with activation of the 
arterial wall endothelium where VCAM-1, ICAM-1 adhesion molecules that express monocytes 
are expressed, and then migrate through the endothelial layer under the influence of various 
proinflammatory chemoattractants. [24] 
Inflammatory reactions induce ROS production, but the reverse is equally true. Moreover, 
components of the reaction interact with synergistic effect. Inflammatory reactions are caused by 
endogenous and exogenous aggressions and are characterized by cellular and vascular events. 
Inflammation and oxidation are processes involved in the pathogenesis of most human disease 
states. These distinct mechanisms are reciprocal and have obvious interactions in the vascular wall. 
[25] Traditionally it is considered that vascular inflammation is initiated at the luminal surface, the 
layer progresses through the media adventicial. [26] There is evidence suggesting that vascular 
adventitia is first activated in a variety of cardiovascular diseases and has key role in shaping and 
evolution of vascular inflammation. [27] Vascular inflammation is part of the defense and tissue 
repair process and is also involved in many pathological conditions such as cardiovascular disease. 
Traditionally vascular inflammation begins with endothelial activation and leukocyte extravasation 
followed by the inflammatory response that spreads from the blood vessels to the environment. 
[28] The production of ROS by NADPH oxidase is achieved via NOX, which differentiates 
NADPH oxidase from other oxidases. Increased production of ROS after induction or activation 
of NADPH oxidase in response to cardiovascular risk factors and inflammation contributes to the 
development of endothelial dysfunction and cardiovascular disease. Vascular endothelium plays 
an important role in regulating the inflammatory response after trauma or haemorrhage. [28] 
Vascular inflammation is implicated in both local and systemic inflammatory conditions. 
Endothelial activation and leukocyte extravasation are key events in vascular inflammation. [29] 
Inflammation, considered as a primary process, plays a fundamental role in all stages of 
atherosclerosis from initiation, evolution, to thrombotic complications. 
There are numerous studies showing that cardiovascular disease (and not only) have an 
important inflammatory component involved in triggering the disease in atheromatous plaque 
formation, development and worsening. In other words, chronic inflammation in the body, 
especially in the cardiovascular system, plays a major role in the development and worsening of 





NOX and atherosclerosis 
Pathogenesis of cardiovascular disease is one of the most complex human diseases. A large 
number of risk factors, physicochemical interactions, cell types, involved biological processes add 
to the complexity of these diseases, including atherosclerosis. Many arguments prove the role of 
oxidative stress and inflammation in promoting atherosclerotic cardiovascular disease. [30] 
Atherosclerosis is a multifactorial disorder that takes place in several stages and involves 
large and medium arteries. Preclinical and clinical investigations show that inflammation operates 
in the pathogenesis of each stage of atherosclerotic events (onset, progression, complexity of 
lesions). It is recognized that vascular oxidative stress as a key factor for the initiation and evolution 
of atherogenesis contributes to the destruction of endothelial cell homeostasis [12, 31, 32, 33], 
which affects the balance between vasoconstriction and vasodilation [12] and initiates a cascade of 
inflammatory processes both by promoting infiltration of inflammatory cells into the wall both 
vascularly and indirectly through the induction of cytokines and other inflammatory mediators that 
eventually lead to structural and functional manifestations of the disease. 
Traditionally, vascular inflammation begins with endothelial activation and leukocyte 
extravasation and ultimately resulting in an inflammatory response that spreads from the blood 
vessels to the environment. NADPH oxidase, the major source of ROS in blood vessel cells, is an 
important factor for the onset and development of vascular disease through endothelial dysfunction, 
inflammation etc. [34] 
Thus, inappropriate activation may contribute to the development of cardiovascular 
diseases such as hypertension, atherosclerosis, diabetes, cardiac hypertrophy, heart failure, 
ischemia-infusion, stroke etc. [35, 36, 37, 38, 39] 
 
Conclusions 
Oxidative changes in the arterial wall may contribute to atherosclerosis when the balance 
between oxidants and antioxidants changes in favor of the increasing of the first. Vascular 
endothelium also produces paracrine factors that maintain vascular homeostasis; one of these 
factors is NO. [40] 
The link between endothelium-derived NO and vascular health is likely to be due to the 
pleiotropic effects of NO on the vascular wall. Common to these processes is the increased 
bioavailability of ROS, low levels of NO (important vasodilator with protective physiological 
role in the vessels, it is crucial for maintenance of vascular endothelium health and function) and 
reduced antioxidant capacity in cardiovascular, renal, nervous systems, etc. The NO 
bioavailability depends on the processes that control NO synthesis and degradation as well as the 
sensitivity of the target tissue to NO. [41] 
Continuously synthesized endothelium has a wide variety of biological properties that 
maintain vascular homeostasis including modulating vascular dilatation tonus, regulating local cell 
growth and protecting vessels from injuries of circulating platelets and cells and multiple 
antiatherosclerotic properties. [27] 
High concentrations of ROS increase premature degradation of endothelial-derived NO 
and NADC production, resulting in endothelial dysfunction. [22] Blocking of NO synthesis with 
NOS inhibitors results in significant peripheral vasoconstriction and increased blood pressure. In 
addition to blood pressure control, NO protects vessels thrombosis by inhibiting platelet 
aggregation and adhesion. 
The initial events in atherogenesis is considered increased transcytosis of low-density 





It is followed by the infiltration of activated inflammatory cells from the coronary 
circulation into the arterial wall. Here they secrete ROS and produce oxidized lipids capable of 
inducing apoptosis of endothelial cells. It is a chronic inflammatory response in the arterial wall, 
mainly by promoting oxidative alteration and other types of LDL alteration [27, 36, 42], changes 
known as atherogenic, and at the same time is one of the early events of atherogenesis. 
Modified lipoproteins are proinflammatory as they signal the endothelial expression of 
leukocyte adhesion molecules and chemokines. In addition, direct and indirect evidence supports 
in particular the contribution of Nox 1, Nox 2 to atherosclerosis. [42, 43] ROS, in particular O2-, is 
involved in the pathogenesis of each stage of vascular lesion formation in atherosclerosis. 
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